Speakers: Ann R. Falsey, MD and Claudia Atherton MT(ASCP)SM----RSV is considered to be a significant threat in pediatric patients as it is a common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children younger than one year. However, RSV infections are also common throughout adult life, and in adults over the age of 65 its clinical impact is significant. CDC reports that RSV infections result in 177,000 hospitalizations and 14,000 deaths annually in adults older than 65 in the U.S. alone.1Join us for this webinar to learn the following: Adult RSV disease burden and clinical manifestations of RSV in adultsRecognize high risk adult populations and understand need for RSV diagnosisHear practical experience from a user who implemented molecular RSV testing and the impact it has had on patient care and managementReferences1. CDC. Accessed Jun 2016. http://www.cdc.gov/media/mmwrnews/2010/n100304.htm
Speaker: Dr. Angella Charnot-Katsikas-----The first FDA-cleared multiplex PCR panel for a large number of respiratory pathogens was first introduced in 2008.1 Laboratories and hospitals have adopted different strategies for offering these assays. Some have implemented strategies to limit the use of the tests and others have offered these assays without limitations. As the adoption of respiratory viral panel grows, there has also been increased attention from payers about the medical necessity and clinical value of these tests. Join us for this webinar to learn the following: Outline some of the available rapid targeted Flu/RSV and full multiplex respiratory viral panels and understand the impact of rapid results in the diagnosis of respiratory infectionsDescribe possible approaches for optimizing the utility of targeted Flu/RSV and full panel tests in the clinical laboratoryLearn reimbursement trends related to panel testsReferences:1. Schreckenberger PC, McAdam AJ. Point-Counterpoint: Large Multiplex PCR Panels Should Be
Speaker: Daniel A.Green MD------The first FDA-cleared multiplex PCR panel for a large number of respiratory pathogens was first introduced in 2008.1 These tests have the ability to detect 12 to 20 pathogens in a single test and some include pathogens that typically cause different manifestations of infection, although they infect the same organ system.Laboratories and hospitals have adopted different strategies for offering these assays. Some have implemented strategies to limit the use of the tests and other laboratories have offered these assays without limitations. Join us for an educational webinar to learn about one center's experience and outcomes related to respiratory viral panels. Learning Objectives:Provide an overview of upper respiratory tract infections (URI’s) and influenza, including approaches to diagnosis and consequences of antibiotic overuse for viral infectionsPresent results from study evaluating the impact of multiplex respiratory virus testing on antimicrobial p
Speaker: Dr. Jane Schwebke -------T. vaginalis is the most common non-viral Sexually Transmitted Infection (STI) in the United States, with an estimated 5-7 million new cases annually.1 Join us for a webinar to learn the following: 1. T. vaginalis infections - prevalence and medical consequences 2. Review of diagnostic testing methods and the rationale for using NAAT methods 3. New CDC STD testing guidelines and future screening considerations 1 Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015:64 (No.3):72.
Speaker: Ferric C. Fang, M.D.--------Clostridium difficile is the most common cause of health care-associated infections in U.S. hospitals and the leading cause of gastroenteritis-associated deaths. This encore presentation of a webinar previously aired in March 2016 will review the evolution of laboratory tests used to diagnose Clostridium difficile infections and consider the advantages and disadvantages of current approaches. Controversies regarding potential over-diagnosis and optimal testing strategies will be discussed.
Speaker: Patricia Gould,RN-----Reduction of Clostridium difficile rates is a common goal of healthcare institutions of all sizes, with ever-evolving strategies aimed at addressing a challenging task. This webinar – the first in a three-part series – presents one such strategy from the perspective of infection prevention. Utilization of on-demand lab testing, protocol-driven processes, and physician education/engagement will be discussed.
Speaker: Dr. Stephen Brecher, PhD. -----Since its discovery in the 1930's, C. difficile has been a vexing pathogen to scientists and clinicians alike, and remains a topic of debate and controversy today. This webinar - the second in the three-part series - examines clinical cases that highlight complex patient management situations, discusses common testing and treatment dilemmas, and outlines evidence-based recommendations for C. difficile infection control and prevention.
Speaker: Dr. Susan Butler-Wu, PhD---As our understanding of C. difficile and C. difficile infection (CDI) continues to evolve, clinical labs find themselves at the center of a shifting debate that carries implications for infection control, hospital reimbursement, public reporting, and most importantly, patient care. This webinar - the final in the three-part series -delves into diagnostic dilemmas, addresses current controversies in testing methodology, and presents testing strategies that account for the strengths and limitations of current technologies.
Speakers: Raquel Martinez, PhD (ABMM) and Daniel A. Green, MD---Please join us and learn about improved respiratory testing algorithms in light of the FDA’s recent reclassification of immunoassay based influenza testing.
With a challenging 2016/17 influenza season behind us, questions have emerged about how to best optimize influenza testing in both the centralized laboratory and point of care (POC) settings. With the recent FDA reclassification of Immunoassay based Rapid Influenza Diagnostic Tests (RIDTs), from class I IVD to class II IVD, and the availability of highly sensitive and rapid PCR-based tests, new opportunities for improved respiratory testing algorithms are emerging.
You will learn about the following:
What is the impact of the FDA RIDT re-classification in the clinical setting?
Why the performance of rapid PCR-based technologies can make a clinical difference
See real-world examples of how to implement and optimize rapid PCR-based technologies in a hub-and-spoke mode
Speaker: Dr. Michael Gelman MD, PhD---Carbapenem-resistant Enterobacteriaceae (CRE) represent an urgent threat to global health.1 While the WHO has identiﬁed CRE as a critical priority for drug development, the CDC has recommended aggressive action to control CRE spread and prevent CRE infections, particularly within healthcare facilities. Newly developed diagnostics have a role at the core of this effort. This webinar explores the clinical signiﬁcance and epidemiology of these highly resistant bacteria and reviews how information available from new diagnostics can inform strategies to control spread.
1. CDC CRE Toolkit. November 2015 Update.
Speaker: Dr. Larissa May - In this webinar, Dr. Larissa May will discuss the diagnosis of sexually transmitted infections in the Emergency Department, the need for evidence-based medicine, and how same-visit treatment and management can be facilitated with on-demand testing for CT/NG.
Speakers: Dr. Nathan Ledeboer, PhD, D(ABMM) and Dr. David Nicolau, PharmD, FCCP, FIDSA- As lab testing technologies, infection control policies, and reporting metrics have evolved over the years, the diagnosis of C. difficile infections has remained a vexing and often controversial topic. Recently updated clinical practice guidelines from IDSA/SHEA attempt to shed new light on a familiar debate, but some of the same challenges remain. This webinar presents expert perspectives from two different areas of clinical practice, with commentary on lab testing dilemmas, antimicrobial stewardship, LabID reporting, and the impact of the new guidelines on current practice.
Cepheid is pleased to welcome CML expert, Associate Professor Susan Branford, PhD to highlight and discuss current topics being encountered in the field of CML monitoring.
Speaker: Dr. Susan Branford, PhD, FFSc (RCPA)
Dr. Branford will discuss the challenges in CML monitoring’ including:
- Reference genes
- Treatment free remission (TFR)
- Monitoring schedules
- And much more!
Speaker: Dr. Debra A. Goff, Pharm.D., FCCP - Antibiotic resistance still remains one of the greatest public health threats today, leading to an estimated 2 million infections and 23,000 deaths per year in the United States.1
This webinar will discuss the importance of diligent antimicrobial stewardship and accuracy of diagnostic tests for the detection of Group A Streptococcus pharyngitis. It will provide commentary on the high confidence that molecular testing affords the antibiotic steward and how the technology can reduce the practice of prescribing antibiotics "just-in-case" there is an infection, especially as testing moves closer to the patient.2
Speakers: Kimberle Chapin, MD, PhD (ABMM) and James Dunn, PhD, D (ABMM)- Globally, 616 million people are diagnosed with group A Streptococcus (GAS) pharyngitis. Of these, 18.1 million cases develop severe GAS disease, and 517,000 people die every year due to GAS disease1. This webinar will explore the evolution of diagnostic testing for the detection of GAS, provide insight into improvements that have been made for rapid testing, and review the consequences of missing positive GAS tests. In addition, clinical case studies will be presented that discuss the consequences of untreated GAS.
1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005 Nov; 5 (11):685-94
Speaker: Kimberle Chapin, MD, PhD (ABMM)-Acute pharyngitis is a frequent complaint seen in the Emergency Department, and group A Streptococcus is the most common bacterial etiology of pediatric pharyngitis. Globally, 616 million people are diagnosed annually with group A Streptococcus (GAS) pharyngitis. Of these, 18.1 million cases develop severe GAS disease, and 517,000 people die every year due to GAS disease.
Understand why the status quo of testing has led to missing GAS cases and overuse of antibiotics for treatment. Learn how new advances in rapid molecular testing can improve your test results and aid in effective management of your patients.
Speaker: Dr. Nicholas Moore, PhD, MLS(ASCP)----The CDC has recommended intensive action to control the spread of carbapenem-resistant Enterobacteriaceae (CRE) and prevent CRE infections, particularly within healthcare facilities.1 Carbapenemase-producing CRE, in particular, are believed to be primarily responsible for the increasing spread of CRE and have been targeted by the CDC for aggressive prevention measures. This webinar explores how to identify patient populations that may benefit from active surveillance testing and compares various testing methods for rapidly identifying carbapenemase-producing CRE.
Speaker: Rochelle Odenbrett---Topic: Standardize Your Diagnostics for Economic & Patient Benefits
Diagnostic technologies represent an opportunity and a challenge when it comes to standardizing the quality of patient care throughout health systems. Learn why and how Sanford Health implemented system-wide standardization of molecular respiratory testing in 70 of their hospital and clinic locations. This 30-minute webinar explores the benefits and pitfalls of standardization initiatives.
Speaker: Sharon Nachman, MD---Topic: Why Test RSV in Adults?
Standardization of quality patient care throughout your hospital provides multiple opportunities for improvement. During respiratory season, most patients at SUNY Stony Brook are tested for RSV. Gain an understanding for this important practice and hear the physician perspective on the importance of testing for RSV in adults.
Globally, 71 million people are living with hepatitis C virus (HCV) infection, but the burden of HCV continues to increase. Between 2015 and 2030, WHO targets include reducing new HCV infections by 80% and HCV deaths by 65%, and increasing HCV diagnoses from <20% to 90% and number of eligible persons receiving HCV treatment from <10% to 80%. To achieve these targets, targeted interventions are needed to enhance HCV testing, linkage to care, and treatment (“the HCV care cascade”). This presentation reviews available evidence on strategies that have been successfully used to enhance HCV testing, linkage to care.
Speaker: Denise Geiger, PhD., DLM(ASCP)----Over the past 20 years there has been a continuous shift toward decentralization of clinical laboratory testing. With recent advances in the speed and accuracy of point-of-care tests, it is now possible to bring molecular infectious disease testing closer to the patient.
This webinar will explore the benefits of molecular point-of-care testing as a means to improving patient outcomes and quality of care. Currently available testing methods will be reviewed, with an emphasis on the importance of lab testing in the era of performance-driven healthcare.
Speaker: Kindra McWilliam-Ross, MSN, APRN, ACNS-BC-----With our aging population in the US, the projection for the number of total hip and total knee arthroplasty procedures is expected to increase exponentially over the next 10 – 15 years. These two commonly performed surgeries often involve significant medical cost and carry a potential risk for postoperative complications.
This webinar will explore the clinical benefits of pre-surgical testing in total hip and total knee arthroplasties and discuss the impact that molecular testing can have on patient outcomes and their quality of care. Several areas of patient management will be covered including Joint Commission Disease Specific Certification, MRSA identification and decolonization, and the key stakeholders required to bring a program together.
Speaker: Eric Wenzler, PharmD, BCPS, BCIDP, AAHIVP----The advent and adoption of rapid diagnostic tests (RDTs) in combination with antimicrobial stewardship programs (ASPs) has revolutionized the care of patients with infectious diseases. For example, in patients with bloodstream infections, the combination of RDT+ASP has been shown to decrease mortality and costs, among other important outcomes.1 Given the mandates for ASP from the Centers for Medicare and Medicaid Services and the Joint Commission, the number of new ASPs is rapidly increasing. These new programs, along with established ASPs, should consider the RDT+ASP combination as the standard of care for their patients.
This webinar will discuss the data supporting the RDT+ASP combination, review RDT systems, and provide guidance on how ASPs can implement and optimize the use of RDTs in virtually any healthcare setting.
Among US women ages 14-49 the prevalence of Trichomonas vaginalis infection is estimated to be 2.3 million, though 85% of women found to have trichomoniasis report no symptoms.1 With varied complications such as increased risk of HSV-2/HIV acquisition, pelvic inflammatory disease and pre-term birth2 it has become increasingly important to identify and treat these patients quickly.
This webinar will explore the renewed interest to screen and diagnose T. vaginalis in women. It will examine current testing methods available and provide updates regarding treatment options.
According to UNAIDS1 the world is embarking on a Fast-Track strategy to end the AIDS epidemic by 2030. There is a strong global consensus that powerful tools now exist to end the AIDS epidemic. HIV treatment can dramatically extend the lifespan of people living with HIV and effectively prevent HIV transmission. HIV testing is a crucial element, where a positive result offers the opportunity to start treatment as soon as possible and a confirmed negative result opens the possibility to start quickly with Pre-Exposure Prophylaxis (PrEP). On the other side, HIV programs will only be effective if community groups and organisations are part of the implementation.
This webinar will explore the benefits of molecular Point-Of-Care HIV testing, within the context of a community centre for men who have sex with men (MSM) and Transgender Women (TW), for three different applications: confirmation of a positive HIV rapid test, detection of an acute HIV infection, and screening of acute infections at the start of PrEP.
CE-IVD. In Vitro Diagnostic Medical Device. Not all tests available in all countries. Not available in the U.S.
Ten years after the 2009 H1N1 outbreak occurred, the IDSA updated the guidelines for the management of influenza. Learn about the new recommendations for diagnostic and treatment protocols. Hear firsthand examples from the laboratory perspective. Learn how this updated approach can streamline laboratory workflows and improve patient care.
This is the first segment of a two-part series. The second webinar explores the IDSA guidelines from a clinician's perspective.
Ten years after the 2009 H1N1 outbreak occurred, the IDSA updated the guidelines for the management of influenza. Learn about the new recommendations for diagnostic and treatment protocols. Hear firsthand examples from the clinician perspective. Learn how this updated approach can improve patient care.
This is the second segment of a two-part series. The first webinar explores the IDSA guidelines from a laboratory perspective.
Proper identification, treatment, and epidemiological measures to combat Carbapenem-Resistant Organisms (CRO) require a better understanding of both your regional and local prevalence rates. Importantly, the accurate identification of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) and the genes encoding for the resistance mechanism may help guide therapeutic strategies and optimize antimicrobial stewardship programs.
This webinar will discuss:
-Current recommendations and criteria for active surveillance and culture confirmation of CRE
-Genotypic testing coupled with therapeutic data for driving antimicrobial decisions
-Impact of PCR testing on hospital CRE indicators and antimicrobial stewardship programs
According to the CDC, chlamydia and gonorrhea are the most common reportable STDs in the US and they are on the rise. While screening for chlamydia and gonorrhea is recommended annually for women under 25, the majority of these infections are asymptomatic.
If left untreated, both symptomatic and asymptomatic infections can lead to complications that include pelvic inflammatory disease, infertility, complications during pregnancy, and increased risk of HIV acquisition.1Visits to the emergency department (ED) for STDs have been increasing and are traditionally treated empirically.2 However, empiric treatment leads to both undertreatment and overtreatment with antibiotics, and loss to follow up is a concern.
This webinar will explore current strategies for the diagnosis and management of sexually transmitted infections in the ED. We will review evidence that supports the need for on-demand testing over batch testing, for chlamydia and gonorrhea. Learn how on-demand testing can drive improved results for a range of hospital services, including antimicrobial stewardship efforts.
At the recent 2019 ECCMID conference held in Amsterdam, Dr Fred Tenover (Vice President of Scientific Affairs here at Cepheid) gave a very well received talk about new Cepheid technologies as well as some recent partnerships which are contributing to the next innovations we are bringing to market.
Some of the exciting topics he covered included, updates to our MRSA and Group B Strep products, new technologies utilized in Cepheid TB products such as 10-coulour detection, melt cure analysis and the upcoming launch of our TB-XDR cartridge as well as the official launch of the Cepheid FleXible cartridge program.
We appreciate that not everyone was able to attend the live talk at ECCMID and through popular demand and interest we have recorded his talk as a Webinar to make it available more widely for our customers.
Hear a national thought leader discuss the benefits of an automated and standardized cartridge-based assay for monitoring of BCR-ABL in CML.
You will learn the clinical benefits of faster and simplified BCR-ABL, monitoring for CML on the GeneXpert, standardization of BCR-ABL monitoring for CML to IS, and the impact of simplified workflows for BCR-ABL monitoring for CML on time to result and reduced variability in results.
Cepheid has developed an automated molecular test for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19. The test leverages the design principles of our current Xpert® Xpress Flu/RSV cartridge technology, in which multiple regions of the viral genome are targeted. Xpert® Xpress SARS-CoV-2 can be utilized in multiple settings where actionable test results are needed to make informed treatment decisions quickly. The test delivers point-of-care results with the same level of performance seen in reference labs.. This webinar discusses the current landscape of diagnosis of the SARS-CoV-2 virus, Cepheid’s EUA approval and a real-world application of the Xpert® Xpress SARS-CoV-2.